BrightPath Biotherapeutics Co (TSE:4594) Quality Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4594 BrightPath Biotherapeutics Co Ltd TSE:4594
47 GF Score
Price 円51.00
GF Value 円4.58
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is BrightPath Biotherapeutics Co Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

BrightPath Biotherapeutics Co Quality Rank Related Terms

TSE:4594
47GF Score
BrightPath Biotherapeutics Co Ltd TSE:4594
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BrightPath Biotherapeutics Co (TSE:4594) Overvalued in 2026?

Based on GuruFocus' analysis, BrightPath Biotherapeutics Co stock appears to be overvalued. The current stock price of 円51.00 is trading 1013.5% above its estimated GF Value™ of 円4.58. GuruFocus considers BrightPath Biotherapeutics Co to be Significantly Overvalued.

Key valuation signals for TSE:4594:

  • Quality Rank:
  • GF Value™: 円4.58 vs. price of 円51.00 (1013.5% above fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the TSE:4594 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BrightPath Biotherapeutics Co Business Description

Address 2-2-4 Kojimachi, Kojimachi Central Building 7th Floor, Chiyoda-ku, Tokyo, JPN
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.
47GF Score

Get the complete analysis for TSE:4594

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円51.00
Price
円4.58
GF Value